HIBRUKA (Orelabrutinib) Approval of HIBRUKA (Orelabrutinib) for the Treatment of R/R MZL in Singapore BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL). Dr. Jasmine Cui, Co-foun ...